v3.26.1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Restricted Cash and Cash Equivalents

The Company's cash balances as of June 30, 2026 and December 31, 2025 consist of the following:

 

 

 

June 30,
2026

 

 

December 31,
2025

 

Cash and cash equivalents

 

$

11,219,217

 

 

$

14,132,027

 

Restricted cash

 

 

575,000

 

 

 

575,000

 

Total cash, cash equivalents, and restricted cash

 

$

11,794,217

 

 

$

14,707,027

 

Summary of Revenue by Major Source

The following table presents revenue by major source:

 

 

 

For the Three Months
Ended June 30,

 

 

For the Six Months
Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Direct to patient

 

$

8,175,345

 

 

$

7,420,904

 

 

$

15,343,823

 

 

$

15,228,681

 

Clinical/Medical providers

 

 

3,529,220

 

 

 

2,231,330

 

 

 

6,474,030

 

 

 

4,255,367

 

Total revenue from contracts with customers

 

$

11,704,565

 

 

$

9,652,234

 

 

$

21,817,853

 

 

$

19,484,048

 

Summary of Potential Common Shares Issuable

Potential dilutive common shares issuable consist of the following at:

 

 

 

June 30,

 

 

 

2026

 

 

2025

 

Stock options

 

 

19,201

 

 

 

22,117

 

Restricted stock units

 

 

1,703,037

 

 

 

1,734,038

 

Other warrants

 

 

1,367,187

 

 

 

 

Total

 

 

3,089,425

 

 

 

1,756,155